Please use this identifier to cite or link to this item:
https://doi.org/10.1093/infdis/jiu359
Title: | Heterologous Prime-Boost Vaccination Using an AS03(B)-Adjuvanted Influenza A(H5N1) Vaccine in Infants and Children < 3 Years of Age | Authors: | Nolan, Terry Izurieta, Patricia Lee, Bee-Wah Chan, Poh Chong Marshall, Helen Booy, Robert Drame, Mamadou Vaughn, David W |
Keywords: | pandemic influenza H5N1 children booster |
Issue Date: | 1-Dec-2014 | Publisher: | Oxford University Press (OUP) | Citation: | Nolan, Terry, Izurieta, Patricia, Lee, Bee-Wah, Chan, Poh Chong, Marshall, Helen, Booy, Robert, Drame, Mamadou, Vaughn, David W (2014-12-01). Heterologous Prime-Boost Vaccination Using an AS03(B)-Adjuvanted Influenza A(H5N1) Vaccine in Infants and Children < 3 Years of Age. JOURNAL OF INFECTIOUS DISEASES 210 (11) : 1800-1810. ScholarBank@NUS Repository. https://doi.org/10.1093/infdis/jiu359 | Abstract: | Background. Protecting young children from pandemic influenza should also reduce transmission to susceptible adults, including pregnant women. Methods. An open study assessed immunogenicity and reactogenicity of a heterologous booster dose of A/Turkey/Turkey/1/2005(H5N1)-AS03B (AS03B is an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion [5.93 mg tocopherol]) in infants and children aged 6 to < 36 months that was given 6 months following 2-dose primary vaccination with A/Indonesia/05/2005(H5N1)-AS03B. Vaccines contained 1.9 μg of hemagglutinin antigen and AS03B. Hemagglutinin inhibition (HI) responses, microneutralization titers, and antineura-minidase antibody levels were assessed for 6 months following the booster vaccination. Results. For each age stratum (defined on the basis of the subject's age at first vaccination as 6 to < 12 months, 12 to < 24 months, and 24 to < 36 months) and overall (n = 113), European influenza vaccine licensure criteria were fulfilled for responses to A/Turkey/Turkey/1/2005(H5N1) 10 days following the booster vaccination. Local pain and fever increased with consecutive doses. Anamnestic immune responses were demonstrated for HI, neutralizing, and antineuraminidase antibodies against vaccine-homologous/heterologous strains. Antibody responses to vaccine-homologous/heterologous strains persisted in all children 6 months following the booster vaccination. Conclusions. Prevaccination of young children with a clade 2 strain influenza A(H5N1) AS03-adjuvanted vaccine followed by heterologous booster vaccination boosted immune responses to the homologous strain and a related clade, with persistence for at least 6 months. The results support a prime-boost vaccination approach in young children for pandemic influenza preparedness. | Source Title: | JOURNAL OF INFECTIOUS DISEASES | URI: | https://scholarbank.nus.edu.sg/handle/10635/245327 | ISSN: | 0022-1899 1537-6613 |
DOI: | 10.1093/infdis/jiu359 |
Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children3 years of a.pdf | 733.91 kB | Adobe PDF | OPEN | Published | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.